• Je něco špatně v tomto záznamu ?

Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

M. Carré, R. Porcher, J. Finke, G. Ehninger, L. Koster, D. Beelen, A. Ganser, L. Volin, S. Lozano, L. Friis, M. Michallet, J. Tischer, E. Olavarria, MJP. Cascon, S. Iacobelli, Y. Koc, P. Jindra, M. Arat, T. de Witte, I. Yakoub Agha, N. Kröger, M. Robin

. 2020 ; 26 (3) : 451-457. [pub] 20191021

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020697

Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative option for myelodysplastic syndromes (MDSs) but is severely limited by nonrelapse mortality (NRM), especially in this mostly older population. Comorbidity assessment is crucial to predict NRM and often assessed with the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI). Moreover, the impact of age on NRM still remains a matter of debate. In recent years, the age at which transplants are made has been progressively increasing, and patients with comorbidities have become more common. Extricating the respective roles of age and comorbidities in toxic mortality is all the more important. This study by the European Group for Blood and Marrow Transplantation registry included 1245 adult patients who underwent a first allogeneic stem cell transplantation for MDSs between 2003 and 2014. Overall, 4-year NRM and overall survival were 32% and 47%, respectively. When considered as continuous predictors, HCT-CI score and age were associated with an increased hazard ratio (HR) for NRM. In multivariate analysis, age band (HR, 1.13; 95% CI, 1.02 to 1.25; P= .016), HCT-CI ≥3 (HR, 1.34; 95% CI, 1.04 to 1.73; P = .022), and Karnofsky Performance Status ≤80 (HR, 2.03; 95% CI, 1.52 to 2.73; P< .0001) were significantly predictive of a worse NRM. In our large cohort, both comorbidities, evaluated by the original HCT-CI score, and chronological age significantly affected NRM. Thus, age should be part of the transplant decision-making process and should be integrated in future scoring systems predicting outcomes of HSCT in MDSs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020697
003      
CZ-PrNML
005      
20220627103604.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bbmt.2019.10.015 $2 doi
035    __
$a (PubMed)31647984
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Carré, Martin $u CHU Grenoble-Alpes, Grenoble, France. Electronic address: mcarre1@chu-grenoble.fr
245    10
$a Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation / $c M. Carré, R. Porcher, J. Finke, G. Ehninger, L. Koster, D. Beelen, A. Ganser, L. Volin, S. Lozano, L. Friis, M. Michallet, J. Tischer, E. Olavarria, MJP. Cascon, S. Iacobelli, Y. Koc, P. Jindra, M. Arat, T. de Witte, I. Yakoub Agha, N. Kröger, M. Robin
520    9_
$a Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative option for myelodysplastic syndromes (MDSs) but is severely limited by nonrelapse mortality (NRM), especially in this mostly older population. Comorbidity assessment is crucial to predict NRM and often assessed with the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI). Moreover, the impact of age on NRM still remains a matter of debate. In recent years, the age at which transplants are made has been progressively increasing, and patients with comorbidities have become more common. Extricating the respective roles of age and comorbidities in toxic mortality is all the more important. This study by the European Group for Blood and Marrow Transplantation registry included 1245 adult patients who underwent a first allogeneic stem cell transplantation for MDSs between 2003 and 2014. Overall, 4-year NRM and overall survival were 32% and 47%, respectively. When considered as continuous predictors, HCT-CI score and age were associated with an increased hazard ratio (HR) for NRM. In multivariate analysis, age band (HR, 1.13; 95% CI, 1.02 to 1.25; P= .016), HCT-CI ≥3 (HR, 1.34; 95% CI, 1.04 to 1.73; P = .022), and Karnofsky Performance Status ≤80 (HR, 2.03; 95% CI, 1.52 to 2.73; P< .0001) were significantly predictive of a worse NRM. In our large cohort, both comorbidities, evaluated by the original HCT-CI score, and chronological age significantly affected NRM. Thus, age should be part of the transplant decision-making process and should be integrated in future scoring systems predicting outcomes of HSCT in MDSs.
650    _2
$a dospělí $7 D000328
650    _2
$a kostní dřeň $7 D001853
650    _2
$a komorbidita $7 D015897
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    12
$a nádory $7 D009369
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a příprava pacienta k transplantaci $7 D019172
655    _2
$a časopisecké články $7 D016428
700    1_
$a Porcher, Raphaël $u Hôpital de l'Hôtel Dieu, Paris, France
700    1_
$a Finke, Jürgen $u University of Freiburg, Freiburg, Germany
700    1_
$a Ehninger, Gerhard, $u Universitaetsklinikum Dresden, Dresden, Germany $d 1952- $7 xx0274365
700    1_
$a Koster, Linda $u European Group for Blood and Marrow Transplantation Data Office, Leiden, The Netherlands
700    1_
$a Beelen, Dietrich $u University Hospital, Essen, Germany
700    1_
$a Ganser, Arnold $u Hannover Medical School, Hannover, Germany
700    1_
$a Volin, Liisa $u HUCH Comprehensive Cancer Center, Helsinki, Finland
700    1_
$a Lozano, Sara $u Hospital Universitario Ramon y Cajal, Madrid, Spain
700    1_
$a Friis, Lone $u Rigshospitalet, Copenhagen, Denmark
700    1_
$a Michallet, Mauricette $u Centre Léon Bérard, Lyon, France
700    1_
$a Tischer, Johanna $u Klinikum Grosshadern, Munich, Germany
700    1_
$a Olavarria, Eduardo $u Imperial College Healthcare NHS Trust, London, UK
700    1_
$a Cascon, Maria Jesús Pascual $u Hospital Regional de Málaga, Málaga, Spain
700    1_
$a Iacobelli, Simona $u University of Tor Vergata, Rome, Italy
700    1_
$a Koc, Yener $u Medical Park Hospitals, Antalya, Turkey
700    1_
$a Jindra, Pavel $u Charles University Hospital, Pilsen, Czech Republic
700    1_
$a Arat, Mutlu $u Florence Nightingale Sisli Hospital, Istanbul, Turkey
700    1_
$a de Witte, Theo $u Radboud University Medical Centre-Nijmegen, Nijmegen, The Netherlands
700    1_
$a Yakoub Agha, Ibrahim $u Unité d'Allogreffe, Maladies du sang, Lille, France
700    1_
$a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany
700    1_
$a Robin, Marie $u Hopital St. Louis, Paris, France
773    0_
$w MED00008579 $t Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation $x 1523-6536 $g Roč. 26, č. 3 (2020), s. 451-457
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31647984 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20220627103602 $b ABA008
999    __
$a ok $b bmc $g 1691302 $s 1141143
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 26 $c 3 $d 451-457 $e 20191021 $i 1523-6536 $m Biology of blood and marrow transplantation $n Biol Blood Marrow Transplant $x MED00008579
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace